Cantor Fitzgerald Forecasts Strong Price Appreciation for Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics (NASDAQ:CAPR) had its price target increased by equities research analysts at Cantor Fitzgerald from $25.00 to $30.00 in a report released on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 61.20% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. Maxim Group boosted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Trading Up 0.6 %

Shares of Capricor Therapeutics stock opened at $18.61 on Thursday. Capricor Therapeutics has a 12 month low of $2.87 and a 12 month high of $23.40. The firm has a market capitalization of $845.08 million, a P/E ratio of -17.56 and a beta of 4.00. The business has a fifty day simple moving average of $15.21 and a two-hundred day simple moving average of $8.46.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently made changes to their positions in CAPR. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the period. State Street Corp lifted its holdings in Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after acquiring an additional 111,291 shares during the period. Point72 Asset Management L.P. purchased a new position in Capricor Therapeutics in the third quarter worth about $3,806,000. PFM Health Sciences LP bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at about $2,324,000. Finally, Renaissance Technologies LLC increased its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.